Intellia Therapeutics Inc (LTS:0JBU)
$ 11.86 0 (0%) Market Cap: 1.22 Bil Enterprise Value: 662.64 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 51/100

Intellia Therapeutics Inc Strategic Collaboration to Develop Novel Genomic Medicines Transcript

Oct 13, 2021 / 02:00PM GMT
Release Date Price: $129.48
Nathalie Delair;Trepo

Good morning, good afternoon, bon jour. Welcome to this webcast to discuss SparingVision's strategic collaboration with Intellia Therapeutics. My name is Nathalie Trepo, Director of Investor Relations and Communications at SparingVision.

Earlier today, Intellia Therapeutics and SparingVision issued a press release detailing the terms of the strategic collaboration we will discuss today. This press release is available on the News section of the SparingVision website. Following today's prepared remarks, we will open up the call for questions. We, therefore, kindly ask that you keep your questions for the Q&A session.

We would also like to remind you that this call is being recorded. A replay will be made available on the SparingVision website.

With that, I will turn it over to Stéphane Boissel, Chief Executive Officer of SparingVision.

M. Stephane Boissel
SparingVision SAS - President, CEO & Chairman

Thank you, Nathalie. Good afternoon or good morning. I'm myself in California so it will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot